- Home
- ARCC vs MRNA Comparison
ARCC vs MRNA Comparison
Compare ARCC & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCC
- MRNA
- Stock Information
- Founded
- ARCC 2004
- MRNA 2010
- Country
- ARCC United States
- MRNA United States
- Employees
- ARCC N/A
- MRNA N/A
- Industry
- ARCC Finance/Investors Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARCC Finance
- MRNA Health Care
- Exchange
- ARCC Nasdaq
- MRNA Nasdaq
- Market Cap
- ARCC 14.7B
- MRNA 16.0B
- IPO Year
- ARCC 2004
- MRNA 2018
- Fundamental
- Price
- ARCC $22.13
- MRNA $28.80
- Analyst Decision
- ARCC Buy
- MRNA Hold
- Analyst Count
- ARCC 10
- MRNA 20
- Target Price
- ARCC $23.06
- MRNA $54.82
- AVG Volume (30 Days)
- ARCC 5.0M
- MRNA 9.3M
- Earning Date
- ARCC 04-30-2025
- MRNA 05-01-2025
- Dividend Yield
- ARCC 8.68%
- MRNA N/A
- EPS Growth
- ARCC N/A
- MRNA N/A
- EPS
- ARCC 2.44
- MRNA N/A
- Revenue
- ARCC $2,990,000,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- ARCC $9.33
- MRNA N/A
- Revenue Next Year
- ARCC $7.07
- MRNA $23.65
- P/E Ratio
- ARCC $9.06
- MRNA N/A
- Revenue Growth
- ARCC 14.38
- MRNA N/A
- 52 Week Low
- ARCC $19.32
- MRNA $29.25
- 52 Week High
- ARCC $23.84
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- ARCC 46.56
- MRNA 34.78
- Support Level
- ARCC $21.55
- MRNA $31.52
- Resistance Level
- ARCC $22.56
- MRNA $34.87
- Average True Range (ATR)
- ARCC 0.35
- MRNA 1.74
- MACD
- ARCC 0.07
- MRNA -0.37
- Stochastic Oscillator
- ARCC 70.59
- MRNA 15.53
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.